About
Curewize Health is a clinical research and commercialization company aiming to advance the personalized treatment of cancers common to children, adolescents, and young adults. The company's lead product family is ProALL, microRNA-based predictive tests for early diagnosis and monitoring of acute lymphoblastic leukemia patients. Curewize's systematic approach is focused on commercializing clinically validated biomarkers to ensure fast market entry. Curewize is also performing R&D for the development of a precision lab test for certain therapies. Altered miRNA patterns can be used to decide on treatment with specific therapies. The company's companion diagnostic test can enable personalized medicine for diverse cancer patients. In addition, the Curewize platform technology is suitable for the development of a diverse portfolio of microRNA lab tests for personalized medicine, diagnosis, and prognosis of numerous diseases. The company is also developing ProState blood tests for the detection of high-accuracy prostate cancer patients. ProState aims to help prevent the over-treatment of prostate cancer patients with radical prostatectomy surgery or radiotherapy.